Lercanidipine Hcl Aurobindo (Lercanidipine Hydrochloride)

Lercanidipine blocks L‑type calcium channels on vascular smooth‑muscle cells, preventing calcium entry that triggers contraction. This selective inhibition causes arterial vasodilation, decreasing peripheral resistance and consequently lowering both systolic and diastolic blood pressure without a pronounced effect on heart rate.

The appropriate dose of Lercanidipine is individualized by the prescribing healthcare professional based on the patient’s blood‑pressure profile, response to therapy, and any co‑existing medical conditions. Dosage adjustments are made according to clinical judgment and regular monitoring.

Safety data for Lercanidipine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Lercanidipine and amlodipine belong to the dihydropyridine class and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may be associated with a lower incidence of peripheral edema, while amlodipine is often dosed once daily and has a well‑established safety profile. Choice depends on individual patient response and physician preference.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed until use.

Lercanidipine is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any specific dietary considerations.

Serious adverse events, although rare, include angioedema, severe hypotension that may lead to syncope or shock, and hepatic dysfunction manifested by elevated liver enzymes or hepatitis. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or signs of liver injury.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, unstable angina, or those taking strong CYP3A4 inhibitors, as these conditions may increase the risk of adverse effects.